Short Message Service (SMS) Reminders for Stroke Secondary Preventative Medications
NCT ID: NCT02336412
Last Updated: 2016-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2015-01-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of a Secondary Stroke Prevention Program
NCT01071408
Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic Stroke
NCT02611440
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
NCT02398656
Safety of Intravenous Thrombolytics in Stroke on Awakening
NCT01643902
Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients
NCT01586702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cholesterol measurement will be made using a finger prick monitor. Participants in the intervention group will be informed that they will receive a daily text message in the morning to remind them about their medications.
Follow-up visits will take place after 1 and 3 months in which the same checks will be carried out as at the baseline visit. At 1 month, the cholesterol level and ambulatory blood pressure level will be repeated. Participants will be encouraged to ask if they have any concerns regarding their medications. At the end of the second visit, participants will be asked if they are satisfied with the care they received during the visits as a quality assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SMS reminder
Daily SMS medication reminder
SMS reminder
Daily SMS medication reminder
No SMS reminder
No daily SMS medication reminder
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SMS reminder
Daily SMS medication reminder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated with any combination of anti-platelet, antihypertensive, and/or lipid-modifying drugs; at least one of which started over the past month
* living in the community
Exclusion Criteria
* patients unable to consent
* patients with no facility to be reminded by SMS or voicemail message
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Glasgow
OTHER
NHS Greater Glasgow and Clyde
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jesse Dawson, BSc MBChB MD
Role: STUDY_DIRECTOR
University of Glasgow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Western Infirmary, NHS Greater Glasgow and Clyde
Glasgow, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN14NE625
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.